Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-26T00:52:24.226Z Has data issue: false hasContentIssue false
  • English
  • Français

Clobazam as Add-on Therapy in Children with Epileptic Encephalopathy

Published online by Cambridge University Press:  10 January 2017

Rosana Carvalho Silva ,
Maria Augusta Montenegro ,
Carlos A.M. Guerreiro  and
Marilisa M. Guerreiro
Rosana Carvalho Silva
Affiliation:
Department of Neurology, State University of Campinas (Unicamp), São Paulo, Brazil
Maria Augusta Montenegro
Affiliation:
Department of Neurology, State University of Campinas (Unicamp), São Paulo, Brazil
Carlos A.M. Guerreiro
Affiliation:
Department of Neurology, State University of Campinas (Unicamp), São Paulo, Brazil
Marilisa M. Guerreiro*
Affiliation:
Department of Neurology, State University of Campinas (Unicamp), São Paulo, Brazil
*
Department of Neurology, FCM/Unicamp, P.O Box 6111, 13083-970, Campinas, SP, Brazil
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Rationale:

Clobazam has been used successfully in adults and children with partial epilepsy. The purpose of this study was to evaluate the safety and efficacy of clobazam as add-on therapy in children with epileptic encephalopathy.

Methods:

This was a retrospective study conducted at the pediatric epilepsy clinic of our university hospital. Children less than 18-years of age with epileptic encephalopathy were included in the study. Clobazam was introduced as add-on therapy, starting with 5 mg/Kg/day and increased in minimally effective doses, up to the maximum tolerated dose. Data were obtained from clinical files and follow-up visits.

Results:

Ninety-seven patients were included in the study (39 girls), aged between 1 and 17-years-old (mean = 9.9). Twenty-six patients had Lennox-Gastaut syndrome, seven had myoclonic astatic epilepsy, nine had West syndrome and, in 57 patients, the type of epileptic encephalopathy could not be determined. Clobazam dosage ranged from 5 to 60 mg/day (mean = 37.5 mg/day). Forty (41%) patients presented with adverse events, most of which were mild and transitory, and clobazam needed to be withdrawn in only 11 patients. Nine (9.2%) patients were seizure-free after clobazam adjunctive therapy. In 11 (11.3%) patients seizure improvement was >75%, in 16 (16.5%) it was >50%, in 17 (17.5%) improvement was <50% and in 44 (45.5%) there was no change in seizure frequency. Three patients were lost to follow-up. In 85% of the patients with seizure improvement, the results lasted for more than one year.

Conclusion:

Clobazam is safe and effective in the treatment of epileptic encephalopathies of childhood.

Résumé:

RÉSUMÉ:Justification:

Le clobazam a été utilisé avec succès chez les adultes et les enfantsatteints d’épilepsie partielle. L’objectif de cetteétude était d’évaluer la sécurité et l’efficacité du clobazamcommetraitement d’appoint chez les enfantsatteints d’épilepsie partielle.

Méthodes:

Il s’agit d’une étude rétrospective chez des enfants de moins de 18 ansatteints d’encéphalopathie épileptique, qui fréquentent la clinique d’épilepsie pédiatrique de notre hôpital universitaire. Le clobazamétait prescritcommetraitement d’appoint avec une dose de départ de 5 mg/Kg/jour. La posologieétait augmentée progressivement d’une dose efficaceminimalejusqu’à la dose maximaletolérée. Les données ontété tirées des dossiers cliniques et des visites de suivi.

Résultats:

Quatre-vingt-dix-sept patients ontété inclusdans l’étude (39 filles et 58 garçons), âgés de 1 à 17 ans (moyenne de 9,9 ans). Vingt-six patients étaient porteurs du syndrome de Lennox-Gastaut, septétaient atteints d’épilepsie astatiquemyoclonique, neuf du syndrome de West et le type d’encéphalopathie épileptique était indéterminé chez 57 patients. La dose de clobazamvariait de 5 à 60 mg/jour (moyenne de 37,5 mg/jour). On a observé des incidents thérapeutiques chez quarante patients (41%) et la plupartontété légers et transitoires. On a dû cesser l’administration du clobazam chez 11 patients seulement. Neuf patients (9,2%) n’avaient plus de crises après l’introduction du clobazamcommetraitement d’appoint. Chez 11 patients (11,3%) l’amélioration était > 75%, > 50% chez 16 (16,5%), < 50% chez 17 (17,5%) et aucunchangementdans la fréquence des crises n’a été observé chez 44 patients (45,5%). Troispatientsontinterrompu le suivi. Chez 85% des patients qui onteuune amélioration des crises, les résultats ont persisté plus d’un an.

Conclusion:

Le clobazamest sûr et efficacedans le traitement des encéphalopathies épileptiques de l’enfance.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 33 , Issue 2 , May 2006 , pp. 209 - 213
Copyright
Copyright © The Canadian Journal of Neurological 2006

References

1. Sander, JW, Shorvon, SD. Incidence and prevalence studies in epilepsy and their methodological problems: a review. J Neurol Neurosurg Psychiatry. 1987; 50(7): 829–39.Google Scholar
2. Camfield, PR, Camfield, CS. The prognosis of childhood epilepsy. Semin Pediatr Neurol. 1994; 1994: 102–10.Google Scholar
3. Barzaghi, F, Fournex, R, Mantegazza, P. Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5- benzodiazepine), a new psychotherapeutic agent. Arzneimittelforschung. 1973; 1973: 683–6.Google Scholar
4. Canadian Study Group for childhood epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenitoin as monotherapy for childhood epilepsy. Epilepsia. 1998; 1998: 952–9.Google Scholar
5. Schmidt, D, Rohde, M, Wolf, P, Roeder-Wanner, U. Clobazam for refractory focal epilepsy. A controlled trial. Arch Neurol. 1986; 1986: 824–6.Google Scholar
6. Schmidt, D. Clobazam for treatment of intractable epilepsy: a critical assessment. Epilepsia. 1994; 35 Suppl 5: S92–5.Google Scholar
7. Remy, C. Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia. 1994; 35 Suppl 5: S88–91.CrossRefGoogle ScholarPubMed
8. Buchanan, N. Clobazam in the treatment of epilepsy: prospective follow-up to 8 years. J Soc Med. 1993; 1993: 378–80.Google Scholar
9. Singh, A, Guberman, AH, Boisvert, D. Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance. Epilepsia. 1995; 1995: 789–803.Google Scholar
10. Reynolds, EH, Heller, AJ, Ring, HA. Clobazam for epilepsy. Lancet. 1988; 2: 565.Google Scholar
11. Heller, AJ, Ring, HA, Reynolds, EH. Factors relating to dramatic response to clobazam therapy in refractory epilepsy. Epilepsy Res. 1988; 1988: 276–80.Google Scholar
12. Satishchandra, P, Varadarajalu, R, Rajaram, P. Long-term use of clobazam in the management of intractable epilepsy: a prospective study. Neurology. 1998; 1998: 284–7.Google Scholar
13. Shimizu, H, Kawasaki, A J, Yuasa, S, Tarao, Y, Kumagai, S, Kanemoto, K. Use of clobazam for the treatment of refractory complex partial seizures. Seizure. 2003; 2003: 2820–6.Google Scholar
14. Montenegro, MA, Ferreira, CM, Cendes, F, LI, LM, Guerreiro, CAM. Clobazam as add-on therapy for temporal lobe epilepsy and hippocampal sclerosis. Can J Neurol Sci. 2005; 32(1): 93–6.Google Scholar
15. Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia. 1991; 1991: 407–16.Google Scholar
16. Dulac, O, Figueroa, D, Rey, E, Arthuis, M. Monotherapy with clobazam in epilepsies in children. Presse Méd. 1983; 1983: 1067–9.Google Scholar
17. Dulac, O. Epileptic encephalopathy. Epilepsia 2001; 42 Suppl 3: S23–6.Google Scholar
18. Thanh, TN, Chiron, C, Dellatolas, G, et al. Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravetás syndrome). Arch Pediatr. 2002; 2002: 1120–7.Google Scholar
19. Schmidt, D, Bourgeois, B. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Safety. 2000; 2000: 467–77.Google Scholar
20. Engel, JJr, ILAE (International League Against Epilepsy). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: a report of the ILAE Task Force on Classification and Terminology. Epilepsia. 2001; 42(6): 796–803.Google Scholar
21. Avanzini, G, Sancini, G, Canafoglia, L, Franceschetti, S. Maturation of cortical physiological properties relevant to epileptogenesis. In: Abnormal Cortical Development and Epilepsy. Spreafico, R, Avanzini, G, Andermann, F, editors. London: John-Libbey and Company; 1999: p. 63–75.Google Scholar
22. Montenegro, MA, Cendes, F, Noronha, AL, Mory, SB, Carvalho, MI, Marques, LH, et al. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia. 2001; 2001: 539–42.Google Scholar
23. Barcs, G, Halasz, P. Effectiveness and tolerance of clobazam in temporal lobe epilepsy. Acta Neurol Scand. 1996; 1996: 88–93.Google Scholar
24. Keene, DL, Whiting, S, Humphreys, P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci. 1990; 1990: 317–9.CrossRefGoogle Scholar
25. Guberman, A, Couture, M, Baschuk, K, Sherwin, A. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. Can J Neurol Sci. 1990; 1990: 311–6.Google Scholar
26. Scott, DF, Moffett, A. The long-term effect of clobazam as adjunctive therapy in epilepsy. Acta Neurol Scand. 1988; 1988: 498–502.Google Scholar
27. Allen, JW, Oxley, J, Robertson, MM, Trimble, MR, Richens, A, Jawad, SS. Clobazam as adjunctive treatment in refractory epilepsy. Br Med. 1983; 1983: 1246–7.Google Scholar
28. Heller, AJ, Ring, HA, Reynolds, EH. Clobazam for refractory epilepsy. Arch Neurol. 1987; 44: 578.Google Scholar
29. Munn, R, Farrel, K. Open study of clobazam in refractory epilepsy. Pediatr Neurol. 1993; 9(6): 465–9.Google Scholar